Back to journals
Academic Journal

Annals of the New York Academy of Sciences

5 Papers Indexed in Blossom

Data updated

Research Footprint

Annals of the New York Academy of Sciences has 5 tracked papers indexed in Blossom (2006–2025) from 24 authors, most often covering Ketamine, Ibogaine and Psilocybin, across Depressive Disorders, Medicinal Chemistry & Drug Development and Schizophrenia.

Published Papers

Open Accessindividual

Perturbing whole-brain models of brain hierarchy: An application for depression following pharmacological treatment

Using whole‑brain models guided by the thermodynamics of mind, the authors perturb model parameters to estimate brain hierarchy and quantify state susceptibility and drivability in major depressive disorder before and after psilocybin or escitalopram treatment. They find escitalopram reduces susceptibility while psilocybin increases it, yet both treatments promote transitions to healthier states, demonstrating the models' potential to inform in‑silico neurostimulation protocols for neuropsychiatric disorders.

Published
Journal
Annals of the New York Academy of Sciences
Authors
Socoró-Garrigosa, M., Sanz Perl, Y., Kringelbach, M. L., Erritzoe, D., Nutt, D. J., Carhart-Harris, R. L., Vohryzek, J., Deco, G.
Open Accessmeta

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants

This review (2015) summarizes the clinical effects of ketamine and its neurobiological underpinnings and mechanisms of action that may provide insight into the neurobiology of depression, relevant biomarkers, and treatment targets, and directions for future research.

Published
Journal
Annals of the New York Academy of Sciences
Authors
Abdallah, C. G., Averill, L. A., Krystal, J. H.
Paywallmeta

A review of the clinical effects of psychotomimetic agents

This early review from 1957 details the clinical effects of what was back then still called psychotomimetics, i.e., psychedelics.

Published
Journal
Annals of the New York Academy of Sciences
Authors
Osmond, H.
Open Accessindividual

Mechanisms of antiaddictive actions of ibogaine

In rat models, ibogaine and its metabolite noribogaine produce lasting reductions in self‑administration of opioids and stimulants (with shorter effects on alcohol and nicotine) and acutely lower nucleus accumbens dopamine. These anti‑addictive effects are attributed to combined actions at kappa‑opioid receptors and NMDA antagonism (for opioids and stimulants), serotonergic uptake inhibition (for alcohol), nicotinic antagonism (for nicotine), and sigma‑2 binding linked to neurotoxicity, with prolonged action from fat sequestration and metabolism to noribogaine.

Published
Journal
Annals of the New York Academy of Sciences
Authors
Glick, S. D., Maisonneuve, I. M.
Open Accessindividual

Pharmacology of MDMA in humans

MDMA at recreational doses (50–150 mg) produces sympathetic stimulation (mydriasis, marked increases in systolic and diastolic blood pressure and heart rate), a biphasic small change in oral temperature, slight dose‑dependent psychomotor impairment, and marked rises in plasma cortisol and prolactin. Peak concentrations and effects occurred at 1–2 h and returned to baseline by 4–6 h, with an elimination half‑life of about 8–9 h.

Published
Journal
Annals of the New York Academy of Sciences
Authors
de la Torre, R., Farré, M., Roset, P. N., Lopez, C. H., Mas, M., Ortuno, J., Menoyo, E., Pizarro, N., Segura, J., Cami, J.

Quick Facts

Papers Indexed
5
h-Index
301
Open Access
No
Publisher
Wiley
Country
United States
Website
Visit